No results for ‘’
Unichem Laboratories Ltd
₹444.30
(0.89%)
Thu, 25 Jun 2026, 07:46 am
Health Technology
Pharmaceuticals: Major
24.5KUnichem Laboratories PE Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 12.71 | 12.89 | 9.12 | 5.36 | 12.95 | 18.08 | 16.81 | 13.85 | 16.26 | 24.56 | 18.68 | 23.97 | 0 | 0 | 0 | 63.44 | 55.58 | 0 | 0 | 35.58 |
| Price to book ratio | 3.20 | 2.37 | 1.14 | 1.19 | 2.82 | 2.77 | 1.81 | 2.15 | 2.54 | 2.13 | 2.11 | 2.45 | 0.75 | 0.52 | 0.42 | 0.85 | 0.70 | 0.84 | 1.41 | 1.99 |
| Price to sales ratio | 1.82 | 1.45 | 0.70 | 0.79 | 2.14 | 2.09 | 1.38 | 1.46 | 1.86 | 1.56 | 1.53 | 3.84 | 3.32 | 1.20 | 1 | 1.81 | 1.46 | 1.54 | 1.97 | 2.35 |
| Price to cash flow ratio | 24.66 | 19.82 | 6.83 | 5.76 | 12.45 | 25.39 | 9.85 | 9.31 | 27.01 | 21.94 | 17.72 | 38.71 | 0 | 0 | 18.08 | 37.41 | 0 | 0 | 0 | 0 |
| Enterprise value | 962Cr | 903Cr | 483Cr | 584Cr | 1606Cr | 1753Cr | 1230Cr | 1537Cr | 2052Cr | 1812Cr | 2027Cr | 2679Cr | 1169Cr | 567Cr | 619Cr | 1978Cr | 1809Cr | 2162Cr | 3527Cr | 5235Cr |
| Enterprise value to EBITDA ratio | 11.02 | 10.18 | 5.62 | 4.32 | 9.27 | 11.94 | 11.27 | 9.26 | 12.62 | 20.73 | 12.18 | 14.83 | 0 | 0 | 0 | 30.59 | 27.08 | 0 | 0 | 22.33 |
| Debt to equity ratio | 0.09 | 0.07 | 0.06 | 0.08 | 0.06 | 0.08 | 0.11 | 0.04 | 0.03 | 0.03 | 0.04 | 0.09 | 0.06 | 0.08 | 0.08 | 0.05 | 0.13 | 0.13 | 0.10 | 0.19 |
| Return on equity % | 29.15 | 19.85 | 12.63 | 24.11 | 23.51 | 16.09 | 11.15 | 16.32 | 16.60 | 8.95 | 11.87 | -7.01 | -7.11 | -0.96 | -2.34 | 1.35 | 1.28 | -8 | -3.85 | 5.71 |
Unichem Laboratories Ltd Price to Earnings Ratio
The Unichem Laboratories Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Unichem Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Unichem Laboratories Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Unichem Laboratories Ltd (NSE: UNICHEMLAB, BSE: 506690) is currently trading at ₹444.30, with a market capitalization of ₹3159.11Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Unichem Laboratories Ltd Price to Earnings Ratio is essential for fundamental analysis.
Unichem Laboratories Ltd Price to Earnings Ratio Current Value
The current Unichem Laboratories Ltd Price to Earnings Ratio stands at 35.58.
The latest Unichem Laboratories Ltd Price to Earnings Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Unichem Laboratories Ltd Price to Earnings Ratio Historical Trend
The Unichem Laboratories Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 35.58
- 2023: 0
- 2022: 0
- 2021: 55.58
- 2020: 63.44
The recent rise in Unichem Laboratories Ltd Price to Earnings Ratio suggests strengthening valuation trends and improving market sentiment.
What Unichem Laboratories Ltd Price to Earnings Ratio Indicates for Investors
The Unichem Laboratories Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Unichem Laboratories Ltd Price to Earnings Ratio Analysis Summary
The Unichem Laboratories Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Unichem Laboratories Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Unichem Laboratories Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.